Unveiling details
Unlocking hope
The comprehensive dual tumor and liquid biopsy profiling platform. DNA+RNA tumor profiling gives broader insight into treatment options. Liquid biopsy profiling enables real-time ctDNA-MRD monitoring and captures emerging variants as the disease evolves. Results are delivered in around 8 working days.
Global scale. Proven quality. Trusted Partnerships.
PLATFORM TECHNOLOGY
One platform from therapy selection to surveillance
01
Sample collection
FFPE tissue and blood.
K-TRACK BO needs blood only.
02
Tissue and liquid biopsy multi-omics sequencing
DNA
All assay
RNA
K-4CARE
Genome-wide features
K-TRACK BO
K-4CARE
03
ctDNA-MRD monitoring and profiling
Monitoring up to 50 personalized mutations
Liquid biopsy profiling of 100+ genes
Limit of detection (LOD): 0.005%
04
AI-powered analysis
K-4CARE predicts the primary site from the RNA profile, with up to 87.7% accuracy.
Multi-modal ctDNA-MRD detection combining mutations, genome-wide mutations, and viral DNA for improved sensitivity.
05
Reports for each decision point
Report 1: profiling
Actionable mutations and biomarkers for therapy selection
Report 2: baseline
Baseline ctDNA level and LB profiling.
Report n: monitoring
Real-time ctDNA status and LB profiling for emerging mutations
Comprehensive biomarker scope
515 + 19,435
K-4CARE sequences 515 DNA genes plus sWGS and the mRNA of 19,435 genes: SNVs, indels, fusions, HRD, TMB, MSI, optional PD-L1, oncoviruses and tissue of origin for CUP.
RNA adds 20% sensitivity for fusions; tissue of origin accuracy is up to 87.7% (Tran 2025).
High-sensitivity MRD
LOD 0.005%
K-4CARE tracks up to 50 personalized mutations, together with 100+ genes in liquid biopsy profiling, viral DNA, and AI-enhanced genome-wide features.
Fast turn-around time (TAT)
8 days
K-4CARE reports are delivered within 8 working days of receiving both the FFPE and blood samples.
PRODUCT PORTFOLIO
Match the test to
your patient’s needs
Which option fits?
What do you need?
Actionable and resistance mutations only
Comprehensive profiling plus ctDNA-MRD monitoring
Is FFPE tumor tissue available?
Yes
No, blood only
Do you need RNA fusions, HRD, TMB, oncoviruses or CUP tissue of origin?
Yes
No
Actionable mutations only
oncoGS
Essential actionable and resistance mutation profiling from FFPE or blood.
Sample
FFPE or 10 mL blood
ctDNA-MRD limit of detection
Not included
Turnaround
7 days profiling
Tumor-naïve
K-TRACK BO
Genomic profiling and MRD monitoring when tissue is not available.
Sample
10–20 mL blood
ctDNA-MRD limit of detection
0.05%
Turnaround
8 days both profiling and
ctDNA-MRD
Tumor-informed
K-TRACK
Affordable genomic profiling plus ctDNA-MRD monitoring.
Sample
FFPE plus 10–20 mL blood
ctDNA-MRD limit of detection
0.01%
Turnaround
5 days profiling,
8 days ctDNA-MRD
Tumor-informed
K-4CARE
Comprehensive DNA and RNA profiling with the most sensitive MRD tracking.
Sample
FFPE plus 10–20 mL blood
ctDNA-MRD limit of detection
0.005%
Turnaround
8 days profiling,
8 days ctDNA-MRD
Gene panel summary
| K-TRACK Tumor-informed |
K-TRACK BO Blood only, tumor-naïve |
K-4CARE DNA + RNA, tumor-informed |
|
|---|---|---|---|
| Sample | FFPE (tumor cellularity ≥20%) plus 10–20 mL blood | 10–20 mL blood (Streck tube) | FFPE plus 10–20 mL blood |
| Cancer scope | 20 solid tumor types | 19 solid tumor types | Profiling: all solid tumors, blood cancers, CUP. MRD: thoracic, digestive, breast and gynecological |
| Genes | 164 tissue; liquid panels of 125, 113 or 149 | Liquid panels of 125, 113 or 149 | 515 DNA + sWGS; 19,435 RNA |
| Biomarkers | Actionable and resistance mutations, MSI, germline (hereditary risk, DPYD) | Same, with MSI for colorectal only | Adds large indels, RNA fusions, HRD, TMB, PD-L1 (optional), oncoviruses, CUP tissue of origin |
| MRD tracking | Up to 20 personalized mutations plus tumor-agnostic panel | Tumor-agnostic panel plus genome-wide features (CNA, fragmentomics) | Up to 50 mutations, viral DNA, AI genome-wide features |
| MRD LOD | 0.01% | 0.05% | 0.005% |
| Turnaround (working days) | 5 profiling (after FFPE); 8 MRD | 8 for all reports | 8 for all reports |
Compare full specifications
| K-TRACK BO Blood only, tumor-naïve |
K-TRACK DNA, Tumor-informed |
K-4CARE DNA + RNA, Tumor-informed |
|
|---|---|---|---|
| Sample | 10-20 mL blood | FFPE plus 10-20 mL blood | FFPE plus 10-20 mL blood |
| Cancer scope | 19 solid tumor types | Profiling: 20 solid tumor types ctDNA-MRD: 19 solid tumor types |
Profiling: all solid tumors, hematologic malignancies, and CUP ctDNA-MRD: 19 solid tumor types |
| Genes |
Liquid panels:
|
FFPE panel: 164 gene Liquid panels:
|
FFPE panel: 515 genes (DNA) + 19,435 genes (RNA) Liquid panels:
|
| Biomarkers profiling |
|
|
|
| ctDNA-MRD Tracking |
|
|
|
| ctDNA-MRD Limit of detection (LOD) | 0.05% | 0.01% | 0.005% |
| Turnaround Time (working days) | 8 days both profiling and ctDNA-MRD | 5 days profiling · 8 days ctDNA-MRD | 8 days profiling · 8 days ctDNA-MRD |
To request our sample report
SCIENTIFIC EVIDENCE
Backed by science
Driven by data
JCO ONCOLOGY ADVANCES
2025
Real-world utilization and performance of ctDNA monitoring in solid tumors
Real-world recurrence prediction across lung, hepatocellular and gastric cancers.
CANCER MEDICINE
2025
Tumor genomic and transcriptomic analysis integrated with ctDNA monitoring
Analytical validation and clinical insights: RNA fusion sensitivity and tissue-of-origin prediction
ESMO Real World Data and Digital Oncology
2024
Clinical trial and real-world evidence in resected colorectal cancer
ctDNA monitoring for recurrence in resected CRC.
RESOURCES
Resources
K-4CARE HCP Flyer
K-TRACK HCP Flyer
oncoGS HCP Flyer
Precision oncology portfolio Patient Flyer
NEWS & INSIGHTS
Featured News
GLOBAL OPERATIONS
Our Global Footprint
Singapore
Vietnam
Hong Kong
Philippines
India
Brazil
CAP-Accredited Laboratory
CAP-Accredited Laboratory
Indonesia
Taiwan
Malaysia
Thailand
Türkiye
USA
Explore
Related Platforms
CANCER SCREENING PLATFORM
SPOT-MAS
The first clinically validated multi-cancer early detection (MCED) test powered by multi-omics.
PRECISION HEALTHCARE PLATFORM
triSure
Comprehensive prenatal screening for selected fetal genetic conditions and maternal health risks, from just 10 mL of maternal blood.
REFERENCES
- Nguyen T, Hoang VAN, Huynh C, et al. A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring. J Liq Biopsy. 2026;14:100496. doi:10.1016/j.jlb.2026.100496.
- Tran NHB, Hoang TPN, Bui VQ, et al. Tumor genomic and transcriptomic analysis integrated with liquid biopsy ctDNA monitoring: analytical validation and clinical insights. Cancer Med. 2025;14(23):e71465. doi:10.1002/cam4.71465.
- Hoang TPN, et al. Combination of BRCA deep-targeted sequencing and shallow whole-genome sequencing to detect homologous recombination deficiency in ovarian cancer. Front Oncol. 2025;15:1593881.
- Hoang VAN, Nguyen N, Nguyen T, et al. Brief report: direct comparison of tumor-informed and tumor-naïve circulating tumor DNA assays for recurrence detection in early-stage non-small cell lung cancer. JTO Clin Res Rep. 2025;7(1):100927. doi:10.1016/j.jtocrr.2025.100927.
- Nguyen T, Hoang VAN, Nguyen TH, et al. Tumor-naïve multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors. Ther Adv Med Oncol. 2025;17:17588359251393090. doi:10.1177/17588359251393090.
- Nguyen ST, Hoang VAN, Trieu VN, et al. Personalized mutation tracking in circulating tumor DNA predicts recurrence in patients with high-risk early breast cancer. NPJ Breast Cancer. 2025;11(1):58. doi:10.1038/s41523-025-00778-z.
- Hoang VAN, Nguyen N, Le DN, et al. Real-world utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors. JCO Oncol Adv. 2025;2. doi:10.1200/OA-24-00084.
- Hoang TPN, Nguyen TA, Tran NHB, et al. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection. Front Mol Biosci. 2024;11:1334808. doi:10.3389/fmolb.2024.1334808.
- Nguyen HT, Hoang VAN, Nguyen TV, et al. Clinical trial and real-world evidence of circulating tumor DNA monitoring to predict recurrence in patients with resected colorectal cancer. ESMO Real World Data Digit Oncol. 2024;6:100076. doi:10.1016/j.esmorw.2024.100076.
- Nguyen HT, Nguyen TV, Hoang VAN, et al. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. Front Oncol. 2022;12:1069296. doi:10.3389/fonc.2022.1069296.
- Tran LS, et al. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detecting and quantifying circulating tumor DNA in patients with lung cancer. PLoS One. 2019;14(12):e0226193.
DISCLAIMER
For healthcare professionals only. Product availability and regulatory status vary by market. Turnaround times are counted in working days from receipt of qualifying samples. All information in the test report should be interpreted by a qualified physician.